ArcherDX at the Companion Diagnostics Symposium 2016
R. Kulesus | 12 Oct, 2016
Development of an NGS-Based Clinical Trial Assay for Entrectinib, a Potent Tyrosine Kinase Inhibitor of ALK, ROS1 and NTRK 1/2/3
Presented by Josh Stahl
Senior Vice President and General Manager, ArcherDX
4:20 pm - 4:50 pm
Pines Manor Ballroom
About the Speaker
Josh was born and raised in Baltimore, MD and studied biochemistry and molecularbiology at West Virginia University. After graduation, he was drawn to Colorado by the snow and mountains, where he attended graduate school at the University of Colorado, Boulder. Josh joined ArcherDX when the company was in its infancy, specifically to be part of something that would make a lasting impact on healthcare. Since then, he has lead the RnD and Operations teams in developing best-in-class NGS applications for translational researchers. In his free time, Josh enjoys skiing, off-roading, mountain biking and playing with his dog Skye.
Recurrent genetic rearrangements involving the tyrosine kinases ALK, ROS1 and NTRK1/2/3 have the potential to be oncogenic drivers. Fusions of these genes tend to be mutually exclusive, and are present in small proportions of a variety of tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer, salivary gland cancer, papillary thyroid cancer, melanoma and sarcoma.These proto-oncogenes are highly promiscuous, forming fusions with multiple different gene partners, and are targetable by tyrosine kinase inhibitors (TKIs).
Entrectinib is a tyrosine kinase inhibitor in clinical development that targets ALK, ROS1 and NTRK1/2/3, and has shown efficacy in a number of different types of solid tumors. We have developed an NGS-based assay to detect both known and novel ALK, ROS1 and NTRK1/2/3 gene fusions in clinical sample types to support clinical trials of entrectinib.
The success of this trial is closely tied to the strong partnership between ArcherDX and Ignyta – constant interaction between the technical and business development teams ensures test accuracy and global adoption of the test to efficiently enroll patients in the trial. As the industry moves to rare target specific compounds, close interaction between pharmaceutical and diagnostic developers will be critical to identify, select, and enroll enough patients for a successful trial outcome.
To address the existing bottlenecks of using NGS in translational research, we’ve created a robust platform that is purpose-built for clinical oncology research.
By combining revolutionary Anchored Multiplex PCR (AMP™) chemistry with an easy-to-use workflow and intuitive software, we are unleashing the power of translational NGS to enable accurate and scalable mutation detection.
Partner with ArcherDX to develop and commercialize a companion diagnostic test for your clinical trial program.
We provide custom target enrichment assays to detect all major types of mutations across genes relevant to your research from a single sample.
Work with our expert assay designers to develop AMP-based NGS CDx tests to suit your needs.